← Back to Search

Other

EVO756 for Chronic Urticaria

Phase 2
Recruiting
Research Sponsored by Evommune, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Confirmed diagnosis of chronic inducible urticaria for at least 3 months
Be older than 18 years old
Must not have
History of diseases other than chronic inducible urticaria or chronic spontaneous urticaria with urticaria or angioedema symptoms, such as urticarial vasculitis, erythema multiforme, cutaneous mastocytosis (urticaria pigmentosa), and hereditary or acquired angioedema
Concurrent use of certain medications, including antihistamines
Timeline
Screening 3 weeks
Treatment Varies
Follow Up day 1 to week 6
Awards & highlights
No Placebo-Only Group

Summary

"This trial will test if EVO756 is safe and effective for treating chronic skin conditions like dermographism and cold urticaria."

Who is the study for?
Adults with chronic inducible urticaria, which includes conditions like symptomatic dermographism and cold urticaria, can participate in this trial. Specific eligibility criteria are not provided.
What is being tested?
The study is testing the safety and effectiveness of a medication called EVO756 taken orally by adults who suffer from chronic inducible urticaria to see if it helps reduce their symptoms.
What are the potential side effects?
Potential side effects for EVO756 are not specified here but generally could include reactions at the site of administration, gastrointestinal issues, headaches, or allergic responses.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have been diagnosed with chronic inducible urticaria for over 3 months.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have a history of skin conditions other than chronic hives.
Select...
I am currently taking antihistamines or similar medications.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~day 1 to week 6
This trial's timeline: 3 weeks for screening, Varies for treatment, and day 1 to week 6 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Safety and tolerability
Secondary study objectives
Change in Critical Temperature Threshold (CTT)
Change in Total Fric Score (TFS)
Change in pruritus severity at the provocation test site

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: EVO756Experimental Treatment1 Intervention

Find a Location

Who is running the clinical trial?

Evommune, Inc.Lead Sponsor
3 Previous Clinical Trials
194 Total Patients Enrolled
~10 spots leftby Mar 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top